Bridgebio Pharma Inc (BBIO)

12:14 PM

What drives BridgeBio Pharma Inc. stock priceConsistent wealth multiplication - jammulinksnews.com

12:14 PM

07:30 AM

Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - Yahoo Finance

07:30 AM

12:16 PM

BridgeBio Pharma Inc. Stock Analysis and ForecastConsistently profitable trades - jammulinksnews.com

12:16 PM

Jul 22, 2025

Is BridgeBio Pharma Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What analysts say about BridgeBio Pharma Inc. stockRobust investment performance - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - The Manila Times

Jul 22, 2025

Jul 22, 2025

BridgeBio Pharma, Inc. Scheduled to Release Q2 Financial Results and Business Updates on August 5, 2025 - Nasdaq

Jul 22, 2025

Jul 22, 2025

BridgeBio, Genetic Disease Pioneer, Sets Q2 2025 Earnings Release DateKey Details Inside - Stock Titan

Jul 22, 2025

Jul 21, 2025

BridgeBio Pharma Stock (BBIO) Opinions on Analyst Buy Ratings and Attruby Launch - Quiver Quantitative

Jul 21, 2025

Jul 21, 2025

BridgeBio stock initiated with Buy rating at Truist on strong Attruby launch - Investing.com Canada

Jul 21, 2025

Jul 21, 2025

BridgeBio Pharma (BBIO) Receives New 'Buy' Rating from Truist Se - GuruFocus

Jul 21, 2025

Jul 18, 2025

BridgeBio Pharma stock maintains Buy rating at H.C. Wainwright after royalty deal - Investing.com Canada

Jul 18, 2025

Jul 16, 2025

These 2 Momentum Stocks Got a Bullish Nod — Here’s Why They Could Reach New Highs - The Globe and Mail

Jul 16, 2025

Jul 16, 2025

Jefferies Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $70 - 富途牛牛

Jul 16, 2025

Jul 15, 2025

Scotiabank Sticks to Its Buy Rating for BridgeBio Pharma (BBIO) - The Globe and Mail

Jul 15, 2025

Jul 15, 2025

Citi reiterates Buy rating on BridgeBio stock ahead of key trial data - Investing.com Canada

Jul 15, 2025

Jul 14, 2025

Trading (BBIO) With Integrated Risk Controls - news.stocktradersdaily.com

Jul 14, 2025

Jul 14, 2025

BridgeBio Pharma (BBIO) Receives Buy Rating from Jefferies | BBIO Stock News - GuruFocus

Jul 14, 2025

Jul 14, 2025

Citi Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $67 - 富途牛牛

Jul 14, 2025

Jul 14, 2025

Jefferies Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN

Jul 14, 2025

Jul 14, 2025

BridgeBio Pharma stock initiated with Buy rating at Jefferies on Attruby potential - Investing.com Canada

Jul 14, 2025

Jul 13, 2025

BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA - MSN

Jul 13, 2025

Jul 13, 2025

BridgeBio Pharma's BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 Therapy - AInvest

Jul 13, 2025

Jul 12, 2025

BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN

Jul 12, 2025

Jul 12, 2025

Helix shareholders to vote on BridgeBio Oncology merger on August 4 By Investing.com - Investing.com Nigeria

Jul 12, 2025

Jul 12, 2025

Helix shareholders to vote on BridgeBio Oncology merger on August 4 - Investing.com Australia

Jul 12, 2025

Jul 11, 2025

Cancer-Focused BridgeBio's $949M SPAC Deal Gets SEC Nod - Law360

Jul 11, 2025

Jul 11, 2025

BridgeBio Oncology's SPAC Merger Advances: SEC Clears Path for Novel Cancer Drug Development Platform - Stock Titan

Jul 11, 2025

Jul 10, 2025

BridgeBio Pharma stock hits 52-week high, reaching $45.53 By Investing.com - Investing.com South Africa

Jul 10, 2025

Jul 09, 2025

BridgeBio Pharma Inc. Rockets on Strategic Moves - StocksToTrade

Jul 09, 2025

Jul 09, 2025

BridgeBio Pharma stock hits 52-week high, reaching $45.53 - Investing.com Australia

Jul 09, 2025

Jul 09, 2025

Oppenheimer Upgrades BridgeBio Pharma to Outperform From Market Perform, Price Target is $60 - MarketScreener

Jul 09, 2025

Jul 09, 2025

BridgeBio Pharma (BBIO) Receives Rating Upgrade to Outperform | BBIO Stock News - GuruFocus

Jul 09, 2025

Jul 09, 2025

BridgeBio (BBIO) Shares Upgraded with Positive Outlook on Future Sales | BBIO Stock News - GuruFocus

Jul 09, 2025

Jul 09, 2025

BridgeBio (BBIO) Upgraded to Outperform with New Price Target | BBIO Stock News - GuruFocus

Jul 09, 2025

Jul 07, 2025

High Growth Tech Stocks To Watch In The US July 2025 - simplywall.st

Jul 07, 2025

Jul 06, 2025

BridgeBio Pharma’s SWOT analysis: stock poised for growth on strong pipeline - Investing.com

Jul 06, 2025

Jul 06, 2025

BridgeBio Pharma (BBIO) Opinions on $300 Million Royalty Financing Deal - Quiver Quantitative

Jul 06, 2025

Jul 02, 2025

BridgeBio Pharma Enters Royalty Purchase Agreement - TipRanks

Jul 02, 2025

Jul 01, 2025

Latham & Watkins Advises BridgeBio on US$300 Million Strategic Royalty Sale of BEYONTTRA® European Royalties - Latham & Watkins LLP

Jul 01, 2025

Jul 01, 2025

Viking Global Investors sells $154 million in BridgeBio Pharma (BBIO) By Investing.com - Investing.com

Jul 01, 2025